Correction: MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L, Russo RIC, Rivas MA, Mercogliano MF, Izzo F, Oakley RH, Pereyra MG, De Martino M, Proietti CJ, Yankilevich P, Roa JC, Guzmán P, Cortese E, Allemand DH, Huang TH, Charreau EH, Cidlowski JA, Schillaci R, Elizalde PV.
Venturutti L, et al. Among authors: schillaci r.
Oncogene. 2023 Dec;42(50):3719. doi: 10.1038/s41388-023-02870-9.
Oncogene. 2023.
PMID: 37978227
No abstract available.